Some of the other players competing in this Blood Glucose Monitoring System Market are Ypsomed (Switzerland), B. Braun (Germany), Nipro (Japan), Sanofi (France), ARKRAY (Japan), Prodigy Diabetes Care (US), ACON Laboratories (US), and Nova Biomedical (US). The global blood glucose monitoring systems market is projected to reach USD 10.58 Billion by 2022 from an estimated USD 8.35 Billion in 2017 at a CAGR of 4.8%.
The Roche (US) dominated the self-monitoring blood glucose systems market in 2016. In the field of blood glucose monitoring, the company offers an extensive range of glucometers, lancing devices, and testing strips under its diabetes care segment. The company has a widespread presence across the North America, Europe, Asia and Latin America. The firm also aims to enter APAC countries like China by establishing manufacturing centers to cater to the rising demand for diabetes diagnosis and treatments across the globe.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=14912252
Medtronic (Ireland) dominated the continuous glucose monitoring systems market in 2016. The company offers products for intensive insulin management, non-invasive diabetes therapies, and other diabetes service & solutions. Medtronic was the first company to introduce the continuous glucose monitoring system in the market. The company focuses on collaborations and agreements to improve the patient experience.
North America would continue to be the largest market for power system simulators followed by Asia Pacific during the forecast period. The global market is dominated by major players including ABB (Switzerland), Schneider Electric (France), Siemens (Germany), GE (US), ETAP (US), RTDS Technologies (Canada), MathWorks (US), OPAL-RT (Canada), and Eaton (Ireland).
